[
  {
    "ts": null,
    "headline": "Argus Trims Zoetis (ZTS) Price Target to $190, Keeps Constructive View",
    "summary": "Zoetis Inc. (NYSE:ZTS) is one of the high-margin pharma stocks to buy now. Argus has trimmed its price target on Zoetis Inc. (NYSE: ZTS) to $190 from $200, maintaining a cautious but constructive view on the animal health giant. While the firm did not change its overall outlook, the revised target reflects a more tempered […]",
    "url": "https://finnhub.io/api/news?id=857448fbb478ebc95062afa8b923a1d69850cc09ada80cd9241d350c0503830c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752864348,
      "headline": "Argus Trims Zoetis (ZTS) Price Target to $190, Keeps Constructive View",
      "id": 136012086,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ZTS",
      "source": "Yahoo",
      "summary": "Zoetis Inc. (NYSE:ZTS) is one of the high-margin pharma stocks to buy now. Argus has trimmed its price target on Zoetis Inc. (NYSE: ZTS) to $190 from $200, maintaining a cautious but constructive view on the animal health giant. While the firm did not change its overall outlook, the revised target reflects a more tempered […]",
      "url": "https://finnhub.io/api/news?id=857448fbb478ebc95062afa8b923a1d69850cc09ada80cd9241d350c0503830c"
    }
  },
  {
    "ts": null,
    "headline": "Why Zoetis (ZTS) Could Beat Earnings Estimates Again",
    "summary": "Zoetis (ZTS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.",
    "url": "https://finnhub.io/api/news?id=a03d9ee48331882973060391c1d51420a8ec8dd3286d970d67979d8c5c0687e9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752855002,
      "headline": "Why Zoetis (ZTS) Could Beat Earnings Estimates Again",
      "id": 136007958,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ZTS",
      "source": "Yahoo",
      "summary": "Zoetis (ZTS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.",
      "url": "https://finnhub.io/api/news?id=a03d9ee48331882973060391c1d51420a8ec8dd3286d970d67979d8c5c0687e9"
    }
  },
  {
    "ts": null,
    "headline": "Looking for Stocks with Positive Earnings Momentum? Check Out These 2 Medical Names",
    "summary": "The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.",
    "url": "https://finnhub.io/api/news?id=727031a680d7bb85464157f2aa503de1f04f422876e6a96c91f8790666d79b2c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752843603,
      "headline": "Looking for Stocks with Positive Earnings Momentum? Check Out These 2 Medical Names",
      "id": 136005986,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ZTS",
      "source": "Yahoo",
      "summary": "The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.",
      "url": "https://finnhub.io/api/news?id=727031a680d7bb85464157f2aa503de1f04f422876e6a96c91f8790666d79b2c"
    }
  },
  {
    "ts": null,
    "headline": "Zoetis: Poised For Growth Yet Priced For Decline (Rating Upgrade To Strong Buy)",
    "summary": "Zoetis leads in animal health with strong EPS growth, key patent-protected drugs, and a rare value entry point. Learn why ZTS stock is upgraded to strong buy.",
    "url": "https://finnhub.io/api/news?id=02e78cf42d29f2da0a70b14a2648f4febbdc001636b97ca5b51a7f0adef87176",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752831011,
      "headline": "Zoetis: Poised For Growth Yet Priced For Decline (Rating Upgrade To Strong Buy)",
      "id": 136001411,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1661329207/image_1661329207.jpg?io=getty-c-w1536",
      "related": "ZTS",
      "source": "SeekingAlpha",
      "summary": "Zoetis leads in animal health with strong EPS growth, key patent-protected drugs, and a rare value entry point. Learn why ZTS stock is upgraded to strong buy.",
      "url": "https://finnhub.io/api/news?id=02e78cf42d29f2da0a70b14a2648f4febbdc001636b97ca5b51a7f0adef87176"
    }
  }
]